

Title (en)

USE OF ANTI-MCAM ANTIBODIES FOR TREATMENT OR PROPHYLAXIS OF GIANT CELL ARTERITIS, POLYMYALGIA RHEUMATICA OR TAKAYASU'S ARTERITIS

Title (de)

VERWENDUNG VON ANTI-MCAM-ANTIKÖRPERN ZUR BEHANDLUNG ODER PROPHYLAXE VON RIESENZELLARTERITIS, POLYMYALGIA RHEUMATICA ODER TAKAYASU-ARTERITIS

Title (fr)

UTILISATION D'ANTICORPS ANTI-MCAM POUR LE TRAITEMENT OU LA PROPHYLAXIE DE L'ARTÉRITE À CELLULES GÉANTES, LA PSEUDO-POLYARTHRITE RHIZOMÉLIQUE OU L'ARTÉRITE DE TAKAYASU

Publication

EP 3350226 A2 20180725 (EN)

Application

EP 16770571 A 20160916

Priority

- US 201562219599 P 20150916
- IB 2016055559 W 20160916

Abstract (en)

[origin: WO2017046776A2] The invention provides anti-MCAM antibodies that inhibit the ability of human MCAM to bind a laminin alpha-4 chain and pharmaceutical compositions and pharmaceutical formulations incorporating the same for use in treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica (PMR) or Takayasu's arteritis, methods of generating such antibodies, and their use in the manufacture of medicaments for treatment of neuroinflammatory disease, autoimmune disease, or cancer.

IPC 8 full level

C07K 16/30 (2006.01)

CPC (source: EP)

A61P 9/00 (2017.12); **A61P 21/00** (2017.12); **A61P 29/00** (2017.12); **C07K 16/3092** (2013.01); **C07K 2317/24** (2013.01); **C07K 2317/34** (2013.01); **C07K 2317/56** (2013.01); **C07K 2317/76** (2013.01); **C07K 2317/92** (2013.01)

Citation (search report)

See references of WO 2017046776A2

Designated contracting state (EPC)

AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

Designated extension state (EPC)

BA ME

DOCDB simple family (publication)

WO 2017046776 A2 20170323; **WO 2017046776 A3 20170504**; CA 2998716 A1 20170323; EP 3350226 A2 20180725; JP 2018530540 A 20181018

DOCDB simple family (application)

IB 2016055559 W 20160916; CA 2998716 A 20160916; EP 16770571 A 20160916; JP 2018513643 A 20160916